The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist

被引:0
作者
V. Reilly
M. Cavanagh
机构
[1] Burnbank,Burnbank Medical Centre
[2] Hamilton,undefined
[3] Lanarkshire,undefined
来源
Pharmacy World and Science | 2003年 / 25卷
关键词
Cardiovascular heart disease; Pharmacist; Practice nurse; Primary care; Scotland; Secondary heart disease prevention;
D O I
暂无
中图分类号
学科分类号
摘要
Background: A primary care practice in the West of Scotland used clinical governance funding to develop a heart disease prevention clinic to target patients with existing heart disease. The practice nurse enlisted the help of the practice pharmacist and the protocol for the clinic was subsequently developed with the involvement of both practitioners. Objective: The aim of this project was to identify and offer health screening and appropriate disease modifying treatment to patients of a primary care (or general medical) practice suffering from cardiovascular heart disease in a clinic run jointly by a practice nurse and pharmacist.Method: Patients identified by the practice pharmacist were offered a full health screen. Their clinical parameters were assessed and appropriate disease modifying drug therapy and lifestyle advice was offered in a review clinic with the practice nurse and pharmacist. Results: the practice pharmacist identified over 212 patients over a 30‐month period. A majority demonstrated hypertension (91%) and angina (89%), while over half (57%) had suffered a heart attack. Statin therapy was modified in a large number of patients (47%) and the number of patients with satisfactory total cholesterol levels has increased from 30% to 57% (p < 0.001). Aspirin and beta‐blocker therapy has been initiated in a significant number of patients (53% and 26% respectively). Twelve patients (6%) stopped smoking; however, many 42% continued to smoke. The general medical doctors (GPs) who demonstrated a change in their own practice readily accepted changes to therapy recommended by the practice nurse and pharmacist. The practice pharmacist offset the additional cost of drug spend on statin therapy by making savings in other therapeutic areas. Conclusion: A secondary heart disease clinic can benefit patients by optimising drug and lifestyle therapy. While the inclusion of a pharmacist confers clinical and economic benefits.
引用
收藏
页码:294 / 298
页数:4
相关论文
共 17 条
[1]  
Wood D(1999)Joint British recommendations on prevention of coronary heart disease in clinical practice Heart 80 S1-S29
[2]  
Durrington P(1990)Diabetes Care and Research in Europe; the St Vincent Declaration Diabetes Med 7 360-70
[3]  
Poulter N(1994)Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients Antiplatelet Trialists' Collaboration. BMJ 308 81-106
[4]  
McInnes G(1998)North of England evidence based Guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ 316 1303-9
[5]  
Rees A(1988)The Beta Blocker Pooling Project (BBPP): subgroup findings from randomised trials in post infarction patients Eur Heart J 9 8-16
[6]  
Wray R.(1997)Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease BMJ 314 1666-74
[7]  
Eccles M(1988)Coronary heart disease; epidemiology of smoking and intervention studies of smoking Am Heart J 115 242-9
[8]  
Freemantle N(2000)The success of an evidence based raional prescribing intervention: A retrospective study Pharm J 265 25-29
[9]  
Mason J.(undefined)undefined undefined undefined undefined-undefined
[10]  
North o. E. A. G. D. G.(undefined)undefined undefined undefined undefined-undefined